Commercialising ground-breaking research
Upstream Medical Technologies will commercialise a suite of novel biomarkers for cardiac disease diagnosis. These biomarkers were developed at the Christchurch Heart Institute (CHI), a University of Otago Centre of Research Excellence, in Christchurch, New Zealand. Researchers at the CHI were the first in the world to discover fragments of proteins called signal peptides in the blood. (Siriwardena, M (2010) Circulation 122; 255).This discovery has lead to a novel class of biomarkers that can be used in diagnosis of various cardiovascular diseases and clinically associated diseases.
From New Zealand to the world
The discoverers filed their first patent in 2007 and are working closely with us to build a sustainable New Zealand-based company around the diagnostics platform that uses their patented technology.
A highly respected team
The CHI is led by Professor Mark Richards who holds the Heart Foundation of New Zealand’s Chair in Cardiovascular Studies. The Translational Biodiscovery Laboratory within the CHI is led by Associate Professor Chris Pemberton. The researchers have an established publication record in this field spanning over 10 years.